| 1 |
<table width="100%" border="0" cellspacing="2"> |
| 2 |
<tr> |
| 3 |
<td> |
| 4 |
<p><img src="p/110.jpg" width="150" height="95" align="left" vspace="5" hspace="3" border="1"><font size="2" face="Arial, Helvetica, sans-serif" color="#000080">This |
| 5 |
year's Organic Chemistry Award Vladimir |
| 6 |
Prelog was presented to Valerije Vrcek, |
| 7 |
Ph.D., a young scientist from the Faculty |
| 8 |
of Pharmacy and Biochemistry in Zagreb for |
| 9 |
his exceptional contribution to synthesis |
| 10 |
of nucleosides, understanding of carbocationic |
| 11 |
rearrangements and NMR spectroscopy of organic |
| 12 |
molecules. The Vladimir Prelog Organic Chemistry |
| 13 |
Award was established in 1996 as a means |
| 14 |
of encouragement for young Croatian scientists |
| 15 |
in the field of organic chemistry. It was |
| 16 |
founded by PLIVA and the Croatian Chemical |
| 17 |
Society to mark 90 years of the birth of |
| 18 |
Vladimir Prelog, the renowned Croatian scientist |
| 19 |
and Nobel Prize Winner.This year's Organic |
| 20 |
Chemistry Award Vladimir</font></p> |
| 21 |
<p><font size="2" face="Arial, Helvetica, sans-serif" color="#000080"> |
| 22 |
Prelog was presented to Valerije Vrcek, |
| 23 |
Ph.D., a young scientist from the Faculty |
| 24 |
of Pharmacy and Biochemistry in Zagreb for |
| 25 |
his exceptional contribution to synthesis |
| 26 |
of nucleosides, understanding of carbocationic |
| 27 |
rearrangements and NMR spectroscopy of organic |
| 28 |
molecules. The Vladimir Prelog Organic Chemistry |
| 29 |
Award was established in 1996</font><font size="2" face="Verdana, Arial, Helvetica, sans-serif" color="#000080"> |
| 30 |
</font></p> |
| 31 |
</td> |
| 32 |
</tr> |
| 33 |
<tr> |
| 34 |
<td height="2"> |
| 35 |
<hr size="1" width="100%"> |
| 36 |
</td> |
| 37 |
</tr> |
| 38 |
<tr valign="top"> |
| 39 |
<td> |
| 40 |
<p align=justify><img height=100 hspace=3 |
| 41 |
src="p/str1.gif" width=150 align=left border=1 vspace="5"><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">Research |
| 42 |
and Development is central to both PLIVA's |
| 43 |
past and future success. For that reason, |
| 44 |
PLIVA pays careful attention to the organization |
| 45 |
of R&D activities, ensuring that research |
| 46 |
and development activities are closely aligned |
| 47 |
to the company's core business.<br> |
| 48 |
<br> |
| 49 |
The prime goal of research at PLIVA is the |
| 50 |
development of new chemical entities which |
| 51 |
can be developed into innovative medicines |
| 52 |
to combat illness and improve the quality |
| 53 |
of life for people around the world. Our |
| 54 |
researchers, assistants and lab technicians |
| 55 |
as well as all employees at PLIVA understand |
| 56 |
that our primary task is helping people.</font> |
| 57 |
<p align=justify><font face="Arial, Helvetica, sans-serif" color="#000080" size="2">PLIVA's |
| 58 |
blockbuster antibiotic <b>azithromycin</b> |
| 59 |
is a good example of how the dedication |
| 60 |
of the PLIVA's R&D staff brought about |
| 61 |
the discovery and development of a medicine |
| 62 |
which is now fighting disease worldwide, |
| 63 |
sold as <b>Sumamed</b> by PLIVA and licensed |
| 64 |
to Pfizer which markets it as <b>Zithromax</b>. |
| 65 |
At this very moment, the staff of PLIVA's |
| 66 |
research institute are working on new, innovative |
| 67 |
and original medicines which will carry |
| 68 |
on PLIVA's battle against disease.</font> |
| 69 |
</td> |
| 70 |
</tr> |
| 71 |
<tr> |
| 72 |
<td height="2"> |
| 73 |
<hr size="1" width="100%"> |
| 74 |
</td> |
| 75 |
</tr> |
| 76 |
<tr valign="top"> |
| 77 |
<td> |
| 78 |
<table cellspacing=0 cellpadding=0 width=360 border=0> |
| 79 |
<tbody> |
| 80 |
<tr> |
| 81 |
<td width=70 height="66"><img height=90 |
| 82 |
src="p/portret_spaventi.gif" width=70 border=0></td> |
| 83 |
<td width=15 height="66"></td> |
| 84 |
<td valign=top align=left width=275 height="66"><br> |
| 85 |
<font face=Arial color=#000080 size=1>RADAN |
| 86 |
SPAVENTI, M.D., Ph.D.<br> |
| 87 |
Research & Development, Direcor<br> |
| 88 |
Management Board, Vice President for |
| 89 |
R&D<br> |
| 90 |
Phone: 3851/3781 078<br> |
| 91 |
Fax: 3851/370 3175<br> |
| 92 |
E-mail: <a |
| 93 |
href="mailto:radan.spaventi@pliva.hr">radan.spaventi@pliva.hr</a><br> |
| 94 |
</font> </td> |
| 95 |
</tr> |
| 96 |
</tbody> |
| 97 |
</table> |
| 98 |
</td> |
| 99 |
</tr> |
| 100 |
<tr> |
| 101 |
<td height="2"> |
| 102 |
<hr size="1" width="100%"> |
| 103 |
</td> |
| 104 |
</tr> |
| 105 |
<tr> |
| 106 |
<td> |
| 107 |
<table cellspacing=0 cellpadding=0 width=360 border=0> |
| 108 |
<tbody> |
| 109 |
<tr> |
| 110 |
<td width=70 height="86"><img height=81 |
| 111 |
src="p/portret_kovacevic.gif" width=70 |
| 112 |
border=0></td> |
| 113 |
<td width=15 height="86"></td> |
| 114 |
<td valign=top align=left width=275 height="86"><br> |
| 115 |
<font face=Arial color=#000080 size=1>KRUNOSLAV |
| 116 |
KOVACEVIC, Ph. D. Chem.<br> |
| 117 |
Research & Development, Deputy to |
| 118 |
Director<br> |
| 119 |
Phone: 3851/3781 105, 3781 027<br> |
| 120 |
Fax: 3851/3703 175<br> |
| 121 |
E-mail: <a |
| 122 |
href="mailto:kruno.kovacevic@pliva.hr">kruno.kovacevic@pliva.hr</a><br> |
| 123 |
</font> </td> |
| 124 |
</tr> |
| 125 |
</tbody> |
| 126 |
</table> |
| 127 |
</td> |
| 128 |
</tr> |
| 129 |
<tr> |
| 130 |
<td height="2"> |
| 131 |
<hr size="1" width="100%"> |
| 132 |
</td> |
| 133 |
</tr> |
| 134 |
<tr> |
| 135 |
<td> |
| 136 |
<table cellspacing=0 cellpadding=0 width=360 border=0> |
| 137 |
<tbody> |
| 138 |
<tr> |
| 139 |
<td width=70><img height=81 src="p/portret_kolega.gif" width=70 border=0></td> |
| 140 |
<td width=15></td> |
| 141 |
<td valign=top align=left width=275><br> |
| 142 |
<font face=Arial color=#000080 size=1>MARKO |
| 143 |
KOLEGA, M.D., Ph.M.<br> |
| 144 |
Research & Development, Deputy to |
| 145 |
Director (+ New Res. Institute Building)<br> |
| 146 |
Phone: 3851/3781 163, 3781 098<br> |
| 147 |
Fax: 3851/3703 175<br> |
| 148 |
GSM/Cell: 38598/289 283<br> |
| 149 |
E-mail: <a href="mailto:marko.kolega@pliva.hr">marko.kolega@pliva.hr</a><br> |
| 150 |
</font> </td> |
| 151 |
</tr> |
| 152 |
</tbody> |
| 153 |
</table> |
| 154 |
</td> |
| 155 |
</tr> |
| 156 |
</table> |
Parent Directory
| 
Revision Log